ASH 2020: CLL
Advertisement
Venetoclax (Ven) has helped patients with chronic lymphocytic leukemia (CLL) achieve improved long-term outcomes with ...
A fixed-duration venetoclax (Ven)-based regimen is considered a standard of care (SOC) option for patients with ...
The introduction of novel agents has given patients with chronic lymphocytic leukemia (CLL) and small lymphocytic ...
The introduction of novel agents has changed the treatment landscape for chronic lymphocytic leukemia (CLL), but these ...
The prognosis for high-risk (HR) chronic lymphocytic leukemia (CLL) is poor. Clinical data have found that small ...
Patients with cancer may experience financial burden due to medical expenses, job disruption/loss, and other factors. ...
A study presented at the 62nd ASH Annual Meeting & Exposition evaluated the risk of cardiovascular (CV) adverse ...
The prognosis for patients with chronic lymphocytic leukemia (CLL) has seen recent improvements, but these benefits ...
Patients with chronic lymphocytic leukemia (CLL) may have an increased risk of atrial fibrillation (AF); among the risk ...
Patients with chronic lymphocytic leukemia (CLL) are at risk for secondary malignancies. However, this risk has not been ...
A study that was presented at the 62nd ASH Annual Meeting & Exposition evaluated real-world outcomes in patients ...
In the randomized, phase III MURANO study, patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated ...
Chemoimmunotherapy (CIT) is a common treatment option for patients with chronic lymphocytic leukemia (CLL) but may ...
Most patients diagnosed with chronic lymphocytic leukemia (CLL) are older; the median age at diagnosis is 70 years. Less ...
Zanubrutinib has been shown to be an effective treatment in patients with chronic lymphocytic leukemia (CLL)/small ...
Certain genomic abnormalities are predictive of poor outcomes in chemoimmunotherapy (CIT) in patients with chronic ...
For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), genetic risk factors may ...
Among patients with chronic lymphocytic leukemia (CLL) who receive chemoimmunotherapy, those with a partial response ...
Venetoclax has been shown to be effective in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), ...
Acalabrutinib is approved for chronic lymphocytic leukemia (CLL), and although patients with CLL have presented durable ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.